Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Postapproval Vaccine Safety Surveillance for COVID-19 Vaccines in the US

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Grace M. Lee, MD, MPH, Stanford University School of Medicine, 300 Pasteur Dr, H306-A, Stanford, CA 94305 (gmlee@stanfordchildrens.org).

Published Online: October 16, 2020. doi:10.1001/jama.2020.19692

Conflict of Interest Disclosures: Drs Lee, Bell, and Romero reported that they are members of the Advisory Committee on Immunization Practices. No other disclosures were reported.

References
1.
Salmon  DA , Akhtar  A , Mergler  MJ ,  et al.  Immunization-safety monitoring systems for the 2009 H1N1 monovalent influenza vaccination program.   Pediatrics. 2011;127(suppl 1):S78-S86.PubMedGoogle ScholarCrossref
2.
Lurie  N , Sharfstein  JM , Goodman  JL .  The development of COVID-19 vaccines: safeguards needed.   JAMA. 2020;324(5):439-440.PubMedGoogle ScholarCrossref
3.
Shimabukuro  TT , Nguyen  M , Martin  D , DeStefano  F .  Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).   Vaccine. 2015;33(36):4398-4405.PubMedGoogle ScholarCrossref
4.
Centers for Disease Control and Prevention (CDC).  Intussusception among recipients of rotavirus vaccine—United States, 1998-1999.   MMWR Morb Mortal Wkly Rep. 1999;48(27):577-581.PubMedGoogle Scholar
5.
Shah  A , Marks  PW , Hahn  SM .  Unwavering regulatory safeguards for COVID-19 vaccines.   JAMA. 2020;324(10):931-932. doi:10.1001/jama.2020.15725PubMedGoogle ScholarCrossref
6.
Yih  WK , Kulldorff  M , Fireman  BH ,  et al.  Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project.   Pediatrics. 2011;127(suppl 1):S54-S64. doi:10.1542/peds.2010-1722IPubMedGoogle ScholarCrossref
7.
Bauchner  H , Malani  PN , Sharfstein  J .  Reassuring the public and clinical community about the scientific review and approval of a COVID-19 vaccine.   JAMA. 2020;324(13):1296-1297.PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close